Skip to main content

Table 5 Proportions of decisions at the end of the trial in seven scenarios when K=3

From: Enrichment Bayesian design for randomized clinical trials using categorical biomarkers and a binary outcome

   

Subset A

Subset B

Subset C

Scenarios

Pattern

Go with EP

Go with SP (efficacy/ interaction)

nA

Go with SP (efficacy/ interaction)

nB

Go with SP (efficacy/ interaction)

nC

Go with A and B

Go with A and C

Go with B and C

Scenario 1

1

0.94

0.02

266.55

0.02

266.43

0.02

267.02

0.00

0.00

0.00

 

2

0.90

0.02

137.03

0.04

268.99

0.04

393.98

0.00

0.00

0.00

 

3

0.87

0.05

474.35

0.06

272.87

0.02

52.78

0.00

0.00

0.00

 

4

0.89

0.04

268.64

0.04

394.67

0.02

136.68

0.00

0.00

0.00

 

5

0.86

0.06

273.72

0.02

53.72

0.05

472.56

0.00

0.00

0.00

Scenario 2

1

0.87

0.04

265.96

0.04

265.86

0.04

268.18

0.00

0.00

0.00

 

2

0.71

0.02

121.46

0.10

269.10

0.16

409.45

0.00

0.00

0.01

 

3

0.44

0.31

480.78

0.21

279.86

0.02

39.36

0.02

0.00

0.00

 

4

0.71

0.09

268.44

0.16

408.75

0.03

122.81

0.01

0.00

0.00

 

5

0.46

0.21

282.57

0.01

39.47

0.30

477.95

0.00

0.01

0.00

Scenario 3

1

0.56

0.00

182.53

0.00

182.83

0.44

434.64

0.00

0.00

0.00

 

2

0.09

0.00

48.59

0.00

98.19

0.90

653.22

0.00

0.00

0.00

 

3

0.82

0.03

444.14

0.03

247.72

0.13

108.13

0.00

0.00

0.00

 

4

0.73

0.01

218.48

0.01

328.03

0.26

253.49

0.00

0.00

0.00

 

5

0.01

0.00

78.30

0.00

13.36

0.98

708.34

0.00

0.00

0.00

Scenario 4

1

0.76

0.00

222.18

0.10

289.78

0.09

288.05

0.00

0.00

0.04

 

2

0.33

0.00

75.06

0.17

276.00

0.32

448.94

0.00

0.00

0.16

 

3

0.46

0.02

342.21

0.50

417.39

0.02

40.39

0.00

0.00

0.00

 

4

0.57

0.01

192.46

0.34

485.06

0.04

122.48

0.00

0.00

0.03

 

5

0.21

0.02

145.08

0.02

34.79

0.73

620.14

0.00

0.00

0.01

Scenario 5

1

0.68

0.00

204.21

0.02

244.22

0.21

351.56

0.00

0.00

0.09

 

2

0.14

0.00

52.01

0.02

183.50

0.54

564.49

0.00

0.00

0.28

 

3

0.63

0.02

379.82

0.30

364.59

0.04

55.59

0.00

0.00

0.01

 

4

0.68

0.00

206.75

0.13

426.00

0.09

167.25

0.00

0.00

0.08

 

5

0.06

0.00

87.94

0.00

17.59

0.91

694.47

0.00

0.00

0.02

Scenario 6

1

0.67

0.01

216.19

0.31

377.23

0.00

206.58

0.00

0.00

0.00

 

2

0.59

0.02

106.91

0.39

402.04

0.00

291.05

0.00

0.00

0.00

 

3

0.22

0.03

296.85

0.75

476.13

0.00

27.02

0.00

0.00

0.00

 

4

0.23

0.02

156.39

0.74

572.35

0.00

71.26

0.00

0.00

0.00

 

5

0.84

0.05

263.31

0.11

98.39

0.00

438.31

0.00

0.00

0.00

Scenario 7

1

0.40

0.00

157.15

0.59

490.36

0.00

152.49

0.00

0.00

0.00

 

2

0.30

0.00

70.66

0.70

527.77

0.00

201.56

0.00

0.00

0.00

 

3

0.06

0.01

182.16

0.93

601.83

0.00

16.00

0.00

0.00

0.00

 

4

0.03

0.00

87.41

0.96

671.51

0.00

41.08

0.00

0.00

0.00

 

5

0.76

0.03

241.06

0.21

147.67

0.00

411.27

0.00

0.00

0.00

  1. The total sample size is set at n= 800, with πk=1/3 and qA=qB=qC=0.5.
  2. *EP: entire population;
  3. *SP: subpopulation (efficacy/interaction) due to the detection of interaction with efficacy in subset k;
  4. nA,nB and nC are the mean sample size in each subset at the end of the study